(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 June 2012 (07.06.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/071612 A1

(51) **International Patent Classification**:
A61K 31/444 (2006.01) *A61K 31/505* (2006.01)
A61K 31/506 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/541 (2006.01) *A61P 7/06* (2006.01)

(21) **International Application Number**:
PCT/AU2011/001551

(22) **International Filing Date**:
29 November 2011 (29.11.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/419,476 3 December 2010 (03.12.2010) US
61/492,485 2 June 2011 (02.06.2011) US

(71) **Applicant** *(for all designated States except US)*: **YM BIOSCIENCES AUSTRALIA PTY LTD** [AU/AU]; 2nd Floor499 St Kilda Road, Melbourne, Victoria 3004 (AU).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **SMITH, Gregg David** [AU/AU]; 14 Gourlay Street, Balaclava, Victoria 3183 (AU). **FIDA, Rose** [AU/AU]; 8a Acacia Street, Glenroy, Victoria 3046 (AU). **KOWALSKI, Mark Marion** [US/US]; 10 Priscilla Lane, Winchester, Massachusetts 01890 (US).

(74) **Agent**: **GRIFFITH HACK**; Level 3509 St Kilda Road, Melbourne, Victoria 3004 (AU).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2012/071612 A1

(54) **Title**: TREATMENT OF JAK2-MEDIATED CONDITIONS

(57) **Abstract**: Described herein is a method for treating a subject experiencing anemia, comprising administering to the subject an amount of N-(cyanomethyl)-4-[2-[[4-(4- morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide [CYT387] or a related compound effective to maintain or elevate the hemoglobin level. The anemic subjects including those afflicted with a myeloproliferative disorder, such as primary myelofibrosis.